SCHEMBL2735408

SCHEMBL2735408

CC(=O)c1c(C(C)C)[nH]c(C)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 1/20 0.45
HSD17B10 Q99714 1/20 0.41
BRD4 O60885 2/20 0.39
BRPF1 P55201 1/20 0.39
CREBBP Q92793 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
GALR3 O60755 1/20 0.36
LMNA P02545 1/20 0.36
NR2F2 P24468 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAPK1 P28482 1/20 0.33
CSNK1A1 P48729 1/20 0.33
CSNK1D P48730 1/20 0.33
CLK2 P49760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8145766 0.75 CYP1A2 (0.67) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL29025896 0.71 CYP1A2 (0.61) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL14123121 0.71 CYP1A2 (0.68) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL11648550 0.71 CYP1A2 (0.50) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL11650981 0.71 CYP1A2 (0.50) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL10077803 0.70 CYP1A2 (0.48) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL11649862 0.68 HSD17B10 (0.47) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL2150911 0.68 CYP1A2 (0.57) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL15177700 0.67 HSD17B10 (0.55) CYP1A2CYP3A4HSD17B10BRD4BRPF1
SCHEMBL11645029 0.67 HSD17B10 (0.55) CYP1A2CYP3A4HSD17B10BRD4BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402331-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-04 EP disclosed
EP-2402009-A1 Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-04 EP disclosed
EP-2366704-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-21 EP disclosed
EP-2364984-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 EP disclosed
WO-2008106139-A1 INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-04 WO disclosed
WO-2008106058-A2 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-04 WO disclosed
WO-2007022459-A2 PROCESSES AND INTERMEDIATES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-02-22 WO disclosed